Stay updated on Celecoxib Impact on SMN2 in SMA Clinical Trial
Sign up to get notified when there's something new on the Celecoxib Impact on SMN2 in SMA Clinical Trial page.

Latest updates to the Celecoxib Impact on SMN2 in SMA Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe study page version was updated to v3.6.3, indicating a new revision of the page. This change does not modify the visible study details.SummaryDifference0.1%

- Check18 days agoChange DetectedThe page revision updated from v3.6.0 to v3.6.2, indicating a minor backend/content-management update. No study details or other user-facing content were changed.SummaryDifference0.1%

- Check33 days agoChange DetectedThe page now indicates that recruitment is closed (no longer looking for participants). Additionally, new help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study) have been added, the Intervention/Treatment label has been reformatted (from 'Intervention / Treatment' to 'Intervention/Treatment'), and a revision note (Revision: v3.6.0) has been posted, reflecting an updated page structure and guidance for users.SummaryDifference0.6%

- Check40 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5 to reflect an internal update to the page template or content management system. No substantive study details or patient-facing information appear to be changed.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page footer revision tag was updated from v3.5.3 to v3.5.4, indicating a minor site update.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page’s footer/version indicator was updated from Revision v3.5.2 to v3.5.3, reflecting a website release rather than a change to the trial information.SummaryDifference0.1%

Stay in the know with updates to Celecoxib Impact on SMN2 in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Celecoxib Impact on SMN2 in SMA Clinical Trial page.